Park Kwonoh, Kim Kyu-Pyo, Park Seongjoon, Chang Heung-Moon
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Department of Internal Medicine, Medical Oncology and Hematology, Pusan National University Yangsan Hospital, Korea.
Asia Pac J Clin Oncol. 2017 Feb;13(1):13-20. doi: 10.1111/ajco.12592. Epub 2016 Oct 22.
It remains unclear whether capecitabine combined with cisplatin would show similar effects compared with standard therapy using gemcitabine and cisplatin in advanced biliary tract cancer (BTC).
Patients with advanced BTC who were treated with first-line chemotherapy at Asan Medical Center were retrospectively analyzed. All patients received either cisplatin followed by gemcitabine on days 1 and 8 every 3 weeks (GP group), or capecitabine on days 1-14 with cisplatin on day 1 every 3 weeks (XP group).
Of the 134 patients who met the inclusion criteria, 78 received XP and 56 were treated with GP. After a median follow-up of 26.2 months, the progression-free survival was 5.7 months for XP versus 4.1 months for GP (hazard ratio [HR] = 0.81, P = 0.31). The overall survival (OS) was 11.0 months for XP versus 9.8 months for GP (HR = 0.84, P = 0.36). In the multivariate analysis, there were no significant differences in PFS and OS between the two groups.
XP seems to be as effective as GP in patients with advanced BTC. The XP regimen is feasible and might offer increased convenience regarding the schedule of drug administration.
在晚期胆管癌（BTC）中，与使用吉西他滨和顺铂的标准疗法相比，卡培他滨联合顺铂是否会显示出相似的效果仍不清楚。
对在峨山医学中心接受一线化疗的晚期BTC患者进行回顾性分析。所有患者每3周接受一次治疗，其中一组在第1天和顺铂联合第8天接受吉西他滨治疗（GP组），另一组在第1 - 14天接受卡培他滨治疗且在第1天接受顺铂治疗（XP组）。
在符合纳入标准的134例患者中，78例接受了XP方案治疗，56例接受了GP方案治疗。中位随访26.2个月后，XP组的无进展生存期为5.7个月，GP组为4.1个月（风险比[HR]=0.81，P = 0.31）。XP组的总生存期（OS）为11.0个月，GP组为9.8个月（HR = 0.84，P = 0.36）。在多变量分析中，两组之间的无进展生存期和总生存期无显著差异。
对于晚期BTC患者，XP方案似乎与GP方案一样有效。XP方案是可行的，并且在给药方案方面可能提供更高的便利性。
